Literature DB >> 10567214

Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

A Esparís-Ogando1, E Díaz-Rodríguez, A Pandiella.   

Abstract

Alterations that affect the ectodomain of receptor tyrosine kinases are often associated with constitutive activation of the enzymic activity of the mutant cell-associated receptor. Since the ectodomain of the ErbB2 receptor tyrosine kinase has been detected as a soluble fragment in the culture supernatant of cells and serum from patients with advanced breast cancer, the possible presence of cell-associated truncated forms of ErbB2 in cancer cells was investigated. Several cell-bound N-terminal truncated forms of ErbB2 were identified in breast cancer cells overexpressing this receptor. The presence of the truncated fragments was independent of lysosomal/proteasomal activity, indicating that classical receptor tyrosine kinase degradation systems were not involved in the N-terminal cleavages. The presence of these truncated forms of ErbB2 was up-regulated by protein kinase C and neuregulin; and down-regulated by phosphatidylinositol 3-kinase, and monoclonal antibodies that target the ectodomain of ErbB2, indicating that N-terminal cleavages of ErbB2 were regulated by multiple mechanisms. The truncated fragments were tyrosine-phosphorylated under resting conditions, and associated with the signalling intermediates Shc and Grb2. It is therefore likely that these truncated forms may be endowed with constitutive activity that allows them to permanently signal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567214      PMCID: PMC1220649     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

1.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

2.  An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.

Authors:  B C Langton; M C Crenshaw; L A Chao; S G Stuart; R W Akita; J E Jackson
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

3.  Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process.

Authors:  A Pandiella; J Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

4.  Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

Authors:  G D Lewis; J A Lofgren; A E McMurtrey; A Nuijens; B M Fendly; K D Bauer; M X Sliwkowski
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

5.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

6.  Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors.

Authors:  J Arribas; L Coodly; P Vollmer; T K Kishimoto; S Rose-John; J Massagué
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

7.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

8.  Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase.

Authors:  K L Guan; J E Dixon
Journal:  Anal Biochem       Date:  1991-02-01       Impact factor: 3.365

9.  An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation.

Authors:  T W Flickinger; N J Maihle; H J Kung
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

10.  Potential sites of PI-3 kinase function in the endocytic pathway revealed by the PI-3 kinase inhibitor, wortmannin.

Authors:  H Shpetner; M Joly; D Hartley; S Corvera
Journal:  J Cell Biol       Date:  1996-02       Impact factor: 10.539

View more
  9 in total

1.  The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

Authors:  Juan C Montero; Ruth Rodríguez-Barrueco; Laura Yuste; Pedro P Juanes; Joana Borges; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Mol Biol Cell       Date:  2006-11-15       Impact factor: 4.138

2.  Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Authors:  Azucena Esparís-Ogando; Elena Díaz-Rodríguez; Juan Carlos Montero; Laura Yuste; Piero Crespo; Atanasio Pandiella
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

3.  Stimulation of cleavage of membrane proteins by calmodulin inhibitors.

Authors:  E Díaz-Rodríguez; A Esparís-Ogando; J C Montero; L Yuste; A Pandiella
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

4.  Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Authors:  Shadan Ali; Sana Al-Sukhun; Bassel F El-Rayes; Fazlul H Sarkar; Lance K Heilbrun; Philip A Philip
Journal:  Life Sci       Date:  2009-03-24       Impact factor: 5.037

5.  Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Authors:  María Jesús Ortiz-Ruiz; Stela Álvarez-Fernández; Tracy Parrott; Sara Zaknoen; Francis J Burrows; Alberto Ocaña; Atanasio Pandiella; Azucena Esparís-Ogando
Journal:  Oncotarget       Date:  2014-11-30

6.  Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases.

Authors:  Li-Mei Chen; Karl X Chai
Journal:  Oncotarget       Date:  2017-04-10

7.  Trastuzumab in the management of early and advanced stage breast cancer.

Authors:  Rupert Bartsch; Catharina Wenzel; Guenther G Steger
Journal:  Biologics       Date:  2007-03

8.  Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.

Authors:  Polina Sysa-Shah; Yi Xu; Xin Guo; Frances Belmonte; Byunghak Kang; Djahida Bedja; Scott Pin; Noriko Tsuchiya; Kathleen Gabrielson
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

9.  Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.

Authors:  D Vernimmen; M Gueders; S Pisvin; P Delvenne; R Winkler
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.